Stock Analysis of Aslan Pharmaceuticals Ltd ADR (ASLN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ASLN
Close 0.444
Change 0.0086 / 1.98 %
Volume 177328
Vol Change -61544.00 / 25.76 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Aslan Pharmaceuticals Ltd ADR
PE (TTM)

-1.41

Very Poor
Price / Book

-24.32

Very Poor
Price / Sales

4.54

Very Poor
Piotroski F Score

6.0

Good
Market Cap

10039.51 K

Enterprise Value

15612.58 K

ROA (TTM)

-92.21

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-321.83

Very Poor
Revenue

0 %

12000.00 K
Net Profit

12.06 %

-45188.26 K
Debt to Equity

-2.02

Very Poor
Altman Z Score

-22.54

Very Poor
Quick Ratio

0

Poor
Cash Ratio

1.62

Indecisive


Highs/Lows of Aslan Pharmaceuticals Ltd ADR
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.411 7.96 % 1.54 % 0.45890.393917-May-2414-May-24
Two Week0.4471 0.760 % 3.42 % 0.460.392406-May-2409-May-24
One Month0.491 9.63 % 5.60 % 0.61210.392422-Apr-2409-May-24
Three Month0.52 14.67 % 5.95 % 2.090.392412-Mar-2409-May-24
Six Months1.03 56.92 % 17.48 % 2.090.39212-Mar-2426-Dec-23
One year4.43 89.98 % 27.52 % 4.40.39219-May-2326-Dec-23
Two year2.275 80.50 % 29.70 % 18.74750.39206-Mar-2326-Dec-23
Five year18.0 97.54 % 85.46 % 18.74750.39206-Mar-2326-Dec-23


Technical View of Aslan Pharmaceuticals Ltd ADR
RSI

46.85

Neutral
MACD

-0.0312

Bullish
ADX

15.42

Bullish
Super Trend

0.542

Mild Bearish
Williams %R

-47.44

Neutral
CCI

-1.09

Neutral


EMA 5

0.425

Strong Bullish
EMA 15

0.433

Strong Bullish
EMA 50

0.510

Mild Bearish
EMA 100

0.656

Mild Bearish
SMA 100

0.567

Mild Bearish
SMA 200

0.996

Mild Bearish
SMA 5 / 20

0.417 / 0.435

Mild Bearish
SMA 15 / 50

0.429 / 0.555

Strong Bearish
SMA 50 / 200

0.555 / 0.996

Mild Bearish




Charts of Aslan Pharmaceuticals Ltd ADR


Returns of Aslan Pharmaceuticals Ltd ADR with Peers
Period / StockASLNCNTGGENEAVTX
1 Week7.96%-5.13%-0.437%-11.61%
1 Mth-9.63%-22.92%-27.85%-29.59%
3 Mth-14.67%-58.52%14.00%115.02%
6mth-56.92%-69.17%-37.96%-55.60%
1 Year-89.98%-53.75%-51.59%-98.57%
2 Year-80.50%-89.31%-64.09%-98.91%
5 Years-97.54%--89.73%-99.94%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aslan Pharmaceuticals Ltd ADR with Peers
Ratio / StockASLNCNTGGENEAVTX
PE-1.41-0.273-95.05-0.0321
P/B-24.321.11205.80-0.249
ROA-92.21-40.38-144.43-304.70
ROE0-404.97-216.520
Debt To Equity-2.026.340.02720.074
Revenue12000.00 K
0 % 		47473.00 K
75.00 % 		8686.12 K
27.83 % 		2249.00 K
87.54 %
Net Income-45188.26 K
12.06 % 		-31841.00 K
32.04 % 		-11750.92 K
64.79 % 		-33188.00 K
20.33 %


Technicals of Aslan Pharmaceuticals Ltd ADR with Peers
Technical / StockASLNCNTGGENEAVTX-
ADX15.4226.6617.5824.07
CMF-0.593-0.724-0.0197-0.127
MFI29.2157.4440.5420.32
RSI46.8530.7642.5535.89
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Aslan Pharmaceuticals Ltd ADR

Address : 3 Temasek Avenue, Singapore, Singapore, 039190
Tel : 65 6817 9598
URL : https://aslanpharma.com
Code : ASLN, ISIN : US04522R1014, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 04_May_2018
Employee Count : 35

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.


Note : All Data Generated at the End of Trading Hours (EOD Data)